Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...

Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...

Rezolute saw its stock drop more than 80% after it revealed the Phase III trial failure. Image credit: Gannvector / Shutterstock.com. Rezolute’s stock has crashed after its only pipeline product ...

GlobalData predicts that Lilly’s retatrutide could reach sales of $15.6bn in 2031. Image credit: Jennie Book / Shutterstock.com. Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight ...

Spinogenix’s first-in-class ALS treatment, SPG302 has been shown to slow disease progression in 82% of patients during a Phase IIa study. Image credit: David Herraez Calzada via Shutterstock.com.

The safety profile of atogepant over the 24-week period aligned with earlier studies of its use in migraine prevention, with no new safety signals observed. Credit: Komsan Loonprom / Shutterstock.com.

Capricor’s stock shot up by 371% after it announced the HOPE-3 data. Image credit: Lightspring / Shutterstock.com. Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of ...

Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...

BMS has now said that data from ADEPT-2 will be available in 2026. Image credit: HJBC / Shutterstock.com. Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of ...

The FDA has debuted a framework that is designed to help companies move away from the use of non-human primate preclinical toxicology testing. Image credit: Deniz_Guler via Shutterstock.com. The US ...

Produodopa is an alternative to AbbVie’s own Duodopa. Credit: Michael Vi via Shutterstock. On 9 January 2024, AbbVie announced the launch of Produodopa ...

ARCH Ventures-backed Paradigm Health has acquired Roche-owned Flatiron Health’s clinical research business, while closing an oversubscribed $78m Series B financing round to incorporate clinical trials ...